JMS-17-2 is a novel, potent and selective antagonist of CX3CR1 with anticancer activity. It inhibits CX3CR1 with an IC50 of 0.32 nM, and has antitumor activities. CX3CR1 is overexpressed in human breast tumors and skeletal metastases. In an animal model bearing MDA-231 tumors, treatment with JMS-17-2 led to a reduction in the number of tumor foci and overall tumor burden, at least as effectively as observed using CRISPRi. Taken together, these results point towards a crucial role of CX3CR1 in dictating seeding, colonization and progression of disseminated breast cancer cells.

纯度：≥98%

CAS：1380392-05-1